Investor Presentation - First Six Months of 2021
102
Investor presentation
First six months of 2021
Rest of World at a glance
Diabetes trend
Diabetes market by value and
Novo Nordisk market share
Rest of World
Novo Nordisk reported sales
Million
DKK
billion
First half of 2021
Sales
(mDKK)
Growth²
30%
200
Total GLP-13
1,733
69%
70
80%
Long-acting insulin4
1,125
15%
30%
150
60
Premix insulin5
1,217
4%
32%1
50
GLP-1
Insulin
60%
Fast-acting insulin
1,070
7%
100
202
155
119
50
NWA
2%1
Human insulin
1,367
13%
40
Total insulin
40%
4,779
10%
30
Other Diabetes care?
240
(23%)
6%1
OAD
20
Diabetes care
6,752
19%
20%
Obesity care
10
642
30%
(SaxendaⓇ)
0
2019
0
0%
Diabetes & Obesity
7,394
20%
May
2030
2045
2016
May
2021
care
Population with diabetes
Diabetes growth rate
Biopharm³
2,429
5%
GLP-1 MS
-Insulin MS
OAD MS
Total
9,823
16%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas
9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of May 2021: Novo Nordisk 56%, Sanofi
24% and Eli Lilly 15%; Competitor GLP-1 value market shares, as of May 2021: Novo
Nordisk 48%, Eli Lilly 49% and AstraZeneca 3%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, May 2021 value
figures
2 At constant exchange rates; 3 Comprises VictozaⓇ, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMixⓇ and
RyzodegⓇ: 6 Comprises NovoRapidⓇ and Fiasp®;7 Comprises Novo NormⓇ and
needles; 8 Comprises primarily NovoSeven®, Novo Eight® and Norditropin®View entire presentation